21世纪经济报道记者周慧 北京报道 1月23日，国务院新闻办公室举行新闻发布会，介绍2025年知识产权工作进展情况。 国家知识产权局副局长芮文彪介绍，2025年共授权发明专利97.2万件，实用新型专利146.1万件，外观设计专利66.6万件。截至2025年底，国内（不含港澳 台）发明专利有效量达到532万件，每万人口高价值发明专利拥有量达到16件。专利密集型产业增加值占GDP比重升至2024年的13.38%，超额完成知识产 权"十四五"规划预期目标。 芮文彪提到，重点区域创新活跃。截至2025年底，长三角地区、京津冀地区和广东省的发明专利有效量分别为173.4万件、91.6万件和89.9万件，合计约占国 内总量的2/3；有效注册商标量合计2805.8万件，占国内总量的一半以上。在世界知识产权组织发布的2025年全球百强创新集群排名中，深圳—香港—广 州、北京、上海—苏州集群分别位居全球第1、第4和第6位。这些区域充分发挥了创新高地的作用，成为中国迈向知识产权强国的战略支点。 图：发布会现场 拍摄：周慧 在创新质量持续提升方面，芮文彪提到，中国国内（不含港澳台）有效发明专利中，高价值发明专利同比增速比总体水平高 ...

Group 1: Market Overview - The structural characteristics of the A-share market in 2026 are becoming increasingly distinct, with changes in sector rotation and investment logic shifting from broad allocation to selective stock picking [1] - Key investment opportunities in 2026 include left-side positioning in the pharmaceutical and cyclical sectors, exploration of new tracks in renewable energy and technology, and the realization of AI applications in media [1] Group 2: Pharmaceutical Sector - The pharmaceutical sector is expected to experience a mild rebound, with upcoming 2025 annual reports and 2026 Q1 reports serving as critical windows to validate the industry's recovery pace [2] - Focus areas include contract research organizations (CROs) and medical devices, particularly those with strong technological attributes and competitive R&D expense ratios [2] - The brain-computer interface field is highlighted as a promising area for future growth, with potential applications expected to emerge as market sentiment stabilizes [2] Group 3: Cyclical Sector - The cyclical industry is likely to show significant differentiation, with opportunities in precious metals and high-quality chemicals [3] - Precious metals, particularly silver, are expected to gain investment value if the gold bull market continues, while small metals related to AI and renewable energy may also present opportunities [3] - The chemical sector is currently at a bottoming phase, with expectations for price recovery, and stock selection should focus on industries with favorable competitive dynamics and new growth points [3] Group 4: Renewable Energy Sector - The lithium battery sector is anticipated to wait for quarterly report catalysts, while space photovoltaic and grid export sectors may open new growth avenues [5] - Space photovoltaic has significant market potential, with domestic companies expected to capture market share due to China's competitive advantage in the global photovoltaic industry [6] - The grid export sector is entering a performance realization phase, particularly for companies targeting the North American market, with expectations for order volume to increase this year [6] Group 5: AI and Media Sector - 2026 is expected to be a pivotal year for the realization of AI applications, with the media sector poised to benefit significantly [7] - Key focus areas include AI in marketing and multi-modal content generation, with the potential for substantial market growth in the video content sector [7][8] - The media sector's AI application market is expected to experience continuous upward movement, driven by competition among major internet companies and advancements in multi-modal technology [8] Group 6: Technology Sector - The AI industry is projected to evolve over the next 3-5 years, with a shift towards commercializing AI applications [9] - The robotics sector should focus on companies achieving performance milestones and those with potential to penetrate core supply chains [9]

Core Viewpoint - The medical ETF (159828) has seen a rise of over 1.3% on January 23, with net inflows exceeding 100 million yuan for five consecutive days, indicating market interest in clinical value and innovation in the healthcare sector [1]. Group 1: Investment Focus - Future investments in the pharmaceutical sector should emphasize the intrinsic logic of clinical value, which addresses the clinical needs of patients and healthcare providers, with both domestic and international policies assigning higher premiums to clinical value [1]. - The pharmaceutical and biotechnology sectors are driven by innovation (including overseas expansion, AI, and new technologies), performance validation, policy benefits, and seasonal market movements, with a short-term focus on innovative drugs and CXO [1]. Group 2: Key Themes and Directions - High-elasticity sub-themes include AI in healthcare/pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs, which are expected to gain traction [1]. - Continuous attention is required on the collaboration outcomes from the JPM conference, clinical data for innovative drugs, and performance realization [1]. - In the realm of innovative medical devices, there is optimism regarding the upgrade of high-end medical equipment and high-value consumables [1]. Group 3: ETF and Index Information - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the A-share market involved in medical devices, medical services, and medical information technology to reflect the overall performance of related listed companies in China's healthcare industry [1].

Core Insights - The article emphasizes the significant influence of Elon Musk on the capital market, particularly through his various ventures, which are seen as investment opportunities. Group 1: Investment Themes - The article identifies five main concepts associated with Elon Musk: electric vehicles (primarily Tesla), robotics (Optimus humanoid robot), commercial space (SpaceX), brain-machine interfaces (Neuralink), and artificial intelligence (xAI) [1][2]. - Tesla's Full Self-Driving (FSD) version 14.2 has achieved "zero takeover" capability across the U.S., and the Austin Robotaxi is currently in testing [1]. - SpaceX is preparing for an IPO with Starlink, which has over 10 million global users and a target valuation of $1.5 trillion [2]. Group 2: Commercial Space Developments - SpaceX plans to launch a second-generation Starlink satellite communication system in 2027, which will enhance capacity by over 100 times and increase data throughput by more than 20 times [3]. - Competitor Blue Origin, led by Jeff Bezos, announced plans to deploy over 5,400 satellites to create a new communication network [3]. - In China, Blue Arrow Aerospace is preparing for an IPO and aims to develop a fully reusable commercial crewed spacecraft, with plans to reduce ticket prices significantly [4]. Group 3: Market Sentiment and Volatility - The commercial space and robotics sectors are characterized as non-profitable and highly volatile, where market movements are driven more by news and developments than by financial performance [4]. - Recent announcements in the commercial space sector have led to a strong rebound in the market, indicating the importance of positive news flow in these industries [4].

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.75% from January 9 to January 22, 2026, lagging behind the index by approximately 0.46 percentage points [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials leading the gains at 3.14% and 2.34%, respectively. In contrast, the pharmaceutical distribution and chemical preparation sectors experienced declines of 3.26% and 2.87% [12][13]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, showing a weekly increase of 60.88%. Conversely, Luyan Pharmaceutical had the largest decline at 39.07% [13][16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry index showed a decline of 0.75%, underperforming the Shanghai and Shenzhen 300 index by 0.46 percentage points [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, while pharmaceutical distribution and chemical preparations faced declines [12]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement and usage [24]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of its drug registration certificate for a new injection, which is expected to enhance its market position [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted as a key area for future growth. Specific companies to watch include Mindray Medical, Yuyuan Medical, and others across various segments [26][28].

Core Insights - The fourth quarter of 2025 saw significant adjustments in the portfolio of renowned fund manager Fu Pengbo, with notable changes in top holdings and investment strategies [1][4]. Group 1: Portfolio Adjustments - In the fourth quarter of 2025, Maiwei Co. replaced China Mobile in Fu Pengbo's top ten holdings, indicating a shift in focus towards high-performing sectors [1]. - Fu Pengbo increased holdings in Cambricon Technologies while reducing positions in several companies including Xinyi Semiconductor, Shenghong Technology, CATL, Tencent Holdings, Dongshan Precision, Luxshare Precision, Alibaba-W, and Juxing Technology [1][3]. Group 2: Market Conditions and Economic Outlook - The central economic work conference and political bureau meeting emphasized maintaining low social financing costs and leaving room for fiscal policy to address future risks, reflecting a cautious yet optimistic outlook for domestic demand policies [1][4]. - The macroeconomic data for the fourth quarter indicated a mixed performance in consumption and investment, with automotive consumption boosted by trade-in subsidies, while real estate remained weak [4]. Group 3: Investment Strategy and Future Outlook - The concentration of the top ten holdings in the fund increased to 70.38%, up from 66.04% in the previous quarter, indicating a strategic focus on fewer, high-potential stocks [5]. - Preparations for the 2026 portfolio include reducing exposure to companies with weak fundamentals and increasing investments in data center cooling, storage, and computing power-related firms, based on industry trends and individual stock research [5]. - The market is expected to see heightened activity in early 2026, with a focus on sectors like AI, non-ferrous metals, and lithium battery materials anticipated to show significant growth [6].

Core Insights - By 2025, China's innovation quality is expected to improve significantly, with the number of high-value invention patents reaching 2.292 million [1] - The growth rate of effective invention patents in fields such as information technology management, computer technology, and medical technology is the fastest, with artificial intelligence patents ranking among the top globally [12][1] - The value added by patent-intensive industries in China has surpassed 18 trillion yuan, increasing its GDP contribution from 11.97% in 2020 to 13.38% in 2024 [7][17] Patent Statistics - As of the end of 2025, the total number of effective invention patents in China (excluding Hong Kong, Macau, and Taiwan) is projected to reach 5.32 million, with a high-value invention patent ownership rate of 16 per 10,000 people [10] - A total of 972,000 invention patents are expected to be granted in 2025, with the examination period reduced to 15 months [8] - The number of patent transfer and licensing registrations reached 697,000 in 2025, marking a year-on-year increase of 13.7% [12][3] Regional Innovation - Key regions such as the Yangtze River Delta, Beijing-Tianjin-Hebei, and Guangdong Province are expected to have effective invention patents of 1.734 million, 916,000, and 899,000 respectively, collectively accounting for about two-thirds of the national total [6] Intellectual Property Trade - From January to November 2025, the total import and export value of intellectual property usage fees reached 382.87 billion yuan, with exports increasing by 23.1% year-on-year [14][3] Trademark Statistics - By the end of 2025, the number of effective registered trademarks in China is projected to be 49.877 million, with the value of Chinese brands among the top 5,000 globally reaching 1.81 trillion USD, ranking second worldwide [16]

Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

Group 1 - The core viewpoint of the article highlights the significant progress made in China's intellectual property (IP) sector by 2025, exceeding the goals set in the 14th Five-Year Plan [3] - By 2025, China is expected to authorize 972,000 invention patents and 1,461,000 utility model patents, with a total of 532 million valid invention patents by the end of 2025, achieving a high-value invention patent ownership of 16 per 10,000 people [3] - The average examination period for trademark registration remains stable at 4 months, with a passing rate exceeding 97%, and the total number of registered trademarks is projected to reach 4,206,000 by 2025 [6] Group 2 - The direct annual output value of geographical indication products in China is close to 1 trillion yuan, marking five consecutive years of growth and contributing significantly to regional economic development [6] - By the end of 2025, China will have recognized 5,066 geographical indication products and approved 7,425 registrations for collective and certification trademarks [8] - The industrialization rate of enterprise invention patents is expected to reach 54% by 2025, with a 13.7% year-on-year increase in patent transfer and licensing registrations [9] Group 3 - China ranks second globally in brand value, with its top 5,000 brands valued at $1.81 trillion [6] - The country has established the largest and most comprehensive network of Technology and Innovation Support Centers (TISC) in collaboration with the World Intellectual Property Organization, with 202 centers [13] - A total of 519 national-level IP public service institutions have been established, covering all provincial levels, and have served over 5 million innovation entities during the 14th Five-Year Plan period [12][13]

Core Insights - The exoskeleton robot industry is experiencing a resurgence, driven by advancements in robotics and AI technology, with a focus on consumer-grade applications and outdoor activities [4][5][7] - Companies like Hypershell, ULS, DNSYS, and ChengTian are emerging as key players in the Chinese exoskeleton market, showcasing their products at major events like CES 2026 [3][4] - Hypershell has positioned itself as a leader in the consumer exoskeleton segment, achieving significant milestones in funding and product delivery [11][13] Industry Overview - Exoskeletons are wearable devices designed to enhance human movement capabilities, with applications primarily in medical rehabilitation and industrial settings [4][5] - The market for consumer-grade exoskeletons is still niche but is gaining traction, particularly among individuals seeking rehabilitation and enhanced mobility [8][11] Technological Developments - Hypershell has introduced innovative products, such as the Hypershell X Ultra, which features advanced AI algorithms and improved battery life, achieving a weight of 1.8 kg and a range of 30 km per battery [13][16] - The industry faces several technical challenges, including the need for better user experience, improved battery life, and the transition from passive to active assistance in exoskeleton functionality [24][26] Market Dynamics - The consumer exoskeleton market is characterized by a lack of standardized regulations, which poses challenges for widespread adoption and market growth [7][8] - Companies are exploring diverse applications for exoskeletons, including outdoor sports, urban commuting, and emergency services, to broaden their market appeal [16][19] Competitive Landscape - Key players in the market include Hypershell, ULS, DNSYS, and ChengTian, each focusing on different aspects of exoskeleton technology, from rehabilitation to outdoor sports [17][21] - The competition is intensifying as new startups enter the market, aiming to innovate and capture consumer interest [5][19]